HONG KONG – South Korea's Alteogen Inc.'s trastuzumab-based antibody-drug conjugate (ADC), ALT-P7, might face heavy competition in the breast cancer space, but the drug gained a potential leg up in gastric cancer, with the FDA awarding orphan designation.